Literature DB >> 22653441

Group I and II mammalian PAKs have different modes of activation by Cdc42.

Yohendran Baskaran1, Yuen-Wai Ng, Widyawilis Selamat, Felicia Tay Pei Ling, Ed Manser.   

Abstract

p21-activated kinases (PAKs) are Cdc42 effectors found in metazoans, fungi and protozoa. They are subdivided into PAK1-like (group I) or PAK4-like (group II) kinases. Human PAK4 is widely expressed and its regulatory mechanism is unknown. We show that PAK4 is strongly inhibited by a newly identified auto-inhibitory domain (AID) formed by amino acids 20 to 68, which is evolutionarily related to that of other PAKs. In contrast to group I kinases, PAK4 is constitutively phosphorylated on Ser 474 in the activation loop, but held in an inactive state until Cdc42 binding. Thus, group II PAKs are regulated through conformational changes in the AID rather than A-loop phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653441      PMCID: PMC3388789          DOI: 10.1038/embor.2012.75

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  31 in total

1.  The mechanism of PAK activation. Autophosphorylation events in both regulatory and kinase domains control activity.

Authors:  C Chong; L Tan; L Lim; E Manser
Journal:  J Biol Chem       Date:  2001-02-22       Impact factor: 5.157

2.  Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6.

Authors:  F Yang; X Li; M Sharma; M Zarnegar; B Lim; Z Sun
Journal:  J Biol Chem       Date:  2001-01-25       Impact factor: 5.157

3.  Specificity profiling of Pak kinases allows identification of novel phosphorylation sites.

Authors:  Ulrike E E Rennefahrt; Sean W Deacon; Sirlester A Parker; Karthik Devarajan; Alexander Beeser; Jonathan Chernoff; Stefan Knapp; Benjamin E Turk; Jeffrey R Peterson
Journal:  J Biol Chem       Date:  2007-03-28       Impact factor: 5.157

Review 4.  A tale of two Paks.

Authors:  Luis E Arias-Romero; Jonathan Chernoff
Journal:  Biol Cell       Date:  2008-02       Impact factor: 4.458

Review 5.  The emerging importance of group II PAKs.

Authors:  Claire M Wells; Gareth E Jones
Journal:  Biochem J       Date:  2010-01-15       Impact factor: 3.857

6.  Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch.

Authors:  M Lei; W Lu; W Meng; M C Parrini; M J Eck; B J Mayer; S C Harrison
Journal:  Cell       Date:  2000-08-04       Impact factor: 41.582

7.  Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor.

Authors:  Grigorios N Paliouras; Monica A Naujokas; Morag Park
Journal:  Mol Cell Biol       Date:  2009-03-16       Impact factor: 4.272

8.  PAK is regulated by PI3K, PIX, CDC42, and PP2Calpha and mediates focal adhesion turnover in the hyperosmotic stress-induced p38 pathway.

Authors:  Perry M Chan; Louis Lim; Edward Manser
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

9.  Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling.

Authors:  Wonshill Koh; Rachel D Mahan; George E Davis
Journal:  J Cell Sci       Date:  2008-03-04       Impact factor: 5.285

10.  Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs.

Authors:  Jeyanthy Eswaran; Wen Hwa Lee; Judit E Debreczeni; Panagis Filippakopoulos; Andrew Turnbull; Oleg Fedorov; Sean W Deacon; Jeffrey R Peterson; Stefan Knapp
Journal:  Structure       Date:  2007-02       Impact factor: 5.006

View more
  51 in total

Review 1.  Kinases as targets for chemical modulators: Structural aspects and their role in spermatogenesis.

Authors:  Pranitha Jenardhanan; Premendu P Mathur
Journal:  Spermatogenesis       Date:  2015-01-26

2.  PAK6 targets to cell-cell adhesions through its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape.

Authors:  Elizabeth M Morse; Xiaowen Sun; Jordan R Olberding; Byung Hak Ha; Titus J Boggon; David A Calderwood
Journal:  J Cell Sci       Date:  2015-11-23       Impact factor: 5.285

Review 3.  Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.

Authors:  Yang-Guang Shao; Ke Ning; Feng Li
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 4.  Signaling, Regulation, and Specificity of the Type II p21-activated Kinases.

Authors:  Byung Hak Ha; Elizabeth M Morse; Benjamin E Turk; Titus J Boggon
Journal:  J Biol Chem       Date:  2015-04-08       Impact factor: 5.157

Review 5.  P21 activated kinases: structure, regulation, and functions.

Authors:  Chetan K Rane; Audrey Minden
Journal:  Small GTPases       Date:  2014-03-21

6.  The subcellular localization of type I p21-activated kinases is controlled by the disordered variable region and polybasic sequences.

Authors:  Xiaowen Sun; Valerie L Su; David A Calderwood
Journal:  J Biol Chem       Date:  2019-08-07       Impact factor: 5.157

Review 7.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

8.  Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate.

Authors:  Byung Hak Ha; Matthew J Davis; Catherine Chen; Hua Jane Lou; Jia Gao; Rong Zhang; Michael Krauthammer; Ruth Halaban; Joseph Schlessinger; Benjamin E Turk; Titus J Boggon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

9.  Group I Paks Promote Skeletal Myoblast Differentiation In Vivo and In Vitro.

Authors:  Giselle A Joseph; Min Lu; Maria Radu; Jennifer K Lee; Steven J Burden; Jonathan Chernoff; Robert S Krauss
Journal:  Mol Cell Biol       Date:  2017-02-01       Impact factor: 4.272

Review 10.  PAK signalling during the development and progression of cancer.

Authors:  Maria Radu; Galina Semenova; Rachelle Kosoff; Jonathan Chernoff
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.